Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

NCT07335328 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

B-cell Non Hodgkin Lymphoma

Interventions

BIOLOGICAL: 1 X 10^6 cells/kg
BIOLOGICAL: 2.5 X 10^6 cells/kg
BIOLOGICAL: Dose expansion: The maximum tolerated dose of CAR-T cells

Sponsor

Medical College of Wisconsin